3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Motor Activity
9
Neoplasms
6
Pancreatic Neoplasms
3
Lung Neoplasms
3
Breast Neoplasms
3
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Peripheral Nervous System Diseases
1
Neurocognitive Disorders
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cognitive Dysfunction
1
Interventions
Specimen Handling
16
Magnetic Resonance Spectroscopy
15
Gemcitabine
14
pembrolizumab
11
Cisplatin
11
Mitomycin
7
Radiation
6
Fluorouracil
6
Cystoscopy
6
enfortumab vedotin
5
avelumab
5
Biopsy
5
dehydroftorafur
4
Transurethral Resection of Bladder
4
Radiotherapy
4
Platinum
4
Nivolumab
4
Mitozytrex
4
Carboplatin
4
1,2-diaminocyclohexaneplatinum II citrate
4
erdafitinib
3
durvalumab
3
cabozantinib
3
Immunoglobulin G
3
Disulfides
3
sapanisertib
2
olaparib
2
eribulin
2
atezolizumab
2
Surveys and Questionnaires
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Exercise
×
30 days
×
Clear all
NCT07548476
2026-05-04
ACE
Dana-Farber Cancer Institute
Phase NA
Not yet recruiting
50 enrolled